Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Vera Therapeutics ( (VERA) ) has provided an update.
Vera Therapeutics, Inc., a biotech firm focused on immunological diseases, has announced the expansion of its atacicept development program. The program will now include two new studies, ORIGIN Extend and PIONEER, targeting multiple autoimmune kidney diseases. Atacicept, designed to inhibit key factors in B-cell activation, has shown positive results in treating IgAN and is expected to enter extended trials and target a broader range of autoimmune diseases. This expansion could significantly change the treatment landscape for patients with autoimmune kidney conditions.
See more data about VERA stock on TipRanks’ Stock Analysis page.
